R&I: Psoriasis - Identifying and Commercializing Market

1. Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation Publisher: GBI Research No of pages: 77 Publish Date: May2014

2. Description GBI Research has released the pharma report: “Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation”, which identifies and assesses first-in-class innovation in the psoriasis development pipeline. Over the last decade, a greater understanding of the underlying pathophysiology of psoriasis has increased emphasis on developing immuneomodulating therapies, as opposed to largely symptomatic treatments. This is currently reflected in a competitive market dominated by multiple disease-modifying biologic therapies (inhibitors of TNF-a and IL-12/IL-23) and generic small-molecule therapies. Despite this, there are significant unmet needs in the market, including safety concerns regarding immunomodulation. This is a particularly important issue for the long-term commercial and clinical success of psoriatic therapeutics, especially for emerging biologics. Another unmet need is ease of drug application, as biologic drug delivery is invasive and painful.

3. Description This allows for pipeline programs that offer a more refined approach to immunomodulation and ease of drug application to gain market share upon entry. In a pipeline of over 200 programs, approximately one third exhibits a novel mechanism of action. Innovative programs target a wide range of molecules implicated in immune signaling, such as cytokines and B and T cell antigens. Several promising first-in-class therapies can selectively modulate specific subsets of immune cells without compromising the entire immune system. In particular, biologics that target a subset of T cells, which are strongly implicated in autoimmune pathophysiology, could allow for specificity of immune suppression and thereby reduce adverse side effects. Based on clinical trials, IL-17-targeted therapies have demonstrated superiority over currently established therapies in achieving advanced clinical endpoints. Other agents which activate regulatory arms of the immune system have also shown promising clinical profiles. Request for discount at: http://www.reportsandintelligence.com/purchase-enquiry/132449

4. Scope • A brief introduction to psoriasis, including symptoms, pathophysiology, and overview of pharmacotherapy • The changing molecular target landscape between market and pipeline and particular focal points of innovation • Overview of how innovative products are contributing to the pipeline and market for psoriasis • Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of phase distribution, molecule type, molecular target, and administration route • Identification and assessment of first-in-class molecular targets with a particular focus on early-stage programs of which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets

5. Reasons to buy • Understanding of the focal shifts in molecular targets in the psoriasis pipeline • Understanding of the distribution of pipeline programs by phase of development, molecule type and molecular target • Scientific and clinical analysis of first-in-class developmental programs • Assessment of the valuations of licensed and co-developed psoriasis treatments • A list of the first-in-class therapies potentially open to deal-making opportunities. • Analysis of financial valuations on licensed or co-developed first-in-class therapies and generics

6. Table Of Content 1 Table of Contents1 Table of Contents 41.1 List of Tables 61.2 List of Figures 62 The Case for Innovation 72.1 Growing Opportunities for Biologic Products 72.2 Diversification of Molecular Targets 72.3 Innovative First-in-Class Product Developments Remain Attractive 72.4 Changes in the Clinical and Commercial Environment Will be More Favorable to Products That Target Niche Indications and Patient Populations 82.5 Innovation in Psoriasis 83 Clinical and Commercial Landscape 93.1 Disease Introduction 93.2 Epidemiology 93.3 Etiology 103.3.1 Genetic Predisposition 10

7. Table Of Content 3.3.2 Environmental Factors 103.4 Pathophysiology 103.4.1 Keratinocytes 103.4.2 Dendritic Cells 113.4.3 T-Cells 113.4.4 Angiogenesis 113.4.5 Growth Factors 113.5 Symptoms and Co-morbidities 123.5.1 Skin Manifestations 123.5.2 Psoriatic Arthritis 123.5.3 Uveitis 123.5.4 Cardiovascular Disease 123.5.5 Psychological Impact 123.6 Diagnosis of Psoriasis 133.6.1 Diagnosis of Psoriatic Arthritis 133.7 Treatment 13 3.7.1 Pharmacological Therapies 13

8. Table Of Content 3.7.2 Topical Medications 133.7.3 Systemic Medications 143.7.4 Non-Pharmacological Therapies 143.7.5 Combination and Rotational Therapies 153.8 Overview of Marketed Products for Psoriasis 163.8.1 Oral Non-Biologic DMARDs 163.8.2 Off-Label Non-Biologic DMARDs 193.8.3 Biologics 193.8.4 Comparative Efficacy and Safety of Marketed Products 233.8.5 Unmet Need 264 Assessment of Psoriasis Pipeline and Innovation 274.1 Overview 274.2 Comparative Efficacy and Safety of Pipeline Programs 29 Get full TOC at: http://www.reportsandintelligence.com/frontier-pharma-psoriasis-identifying-and-commercializing-first-in-class-innovation-market/table-of-contents

9. FOR MORE DETAILS Visit us at : http://www.reportsandintelligence.com/frontier-pharma-psoriasis-identifying-and-commercializing-first-in-class-innovation-market Stay With Us: • TELEPHONE: Direct: +1 (617) 674-4143 • Toll Free: +1 (855) 711-1555E-MAIL: sales@reportsandintelligence.com 5933 NE Win Sivers Drive,#205, Portland, OR 97220United States